Top

Published in:

Open Access 01-11-2018 | Review Article

Bone morphogenetic proteins in fracture repair

Authors: Ivo Dumic-Cule, Mihaela Peric, Lucija Kucko, Lovorka Grgurevic, Marko Pecina, Slobodan Vukicevic

Published in: International Orthopaedics | Issue 11/2018

Abstract

Bone fractures represent a significant medical morbidity among aged population with osteoporosis. Bone morphogenetic proteins (BMPs) are suggested to have therapeutic potential to enhance fracture healing in such patients. Though BMP-mediated fracture healing has been well-documented in preclinical models, there has been no clinical study that demonstrated unequivocally that indeed a BMP when presented with an appropriate scaffold could provide basis for robust outcome for delayed or non-union diaphyseal bone fractures. This review presents a comprehensive insight towards the existing knowledge on the role of BMP signaling in bone formation and maintenance. Also therapeutic options based on BMP biology are discussed.

A novel osteoinductive autologous bone graft substitute (ABGS) aimed to accelerate bone regeneration was developed and is currently being tested in the clinical setting. It comprises of a biologically compatible autologous carrier made from the patient’s peripheral blood (autologous blood coagulum, ABC) and of rhBMP6 as an active ingredient. Such formulation circumvents the use of animal-derived materials, significantly limits inflammatory processes common in commercial bone devices and renders the carrier flexible, malleable, and injectable ensuring the ease of use. The ongoing clinical trials result will provide more detailed insights into the safety, tolerability, pharmacokinetics, and bone healing effects in humans and potentially provide novel and safe therapeutic options for bone repair.

Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J et al (2013) Osteoporosis in the European Union: a compendium of country-specific reports. Arc Osteoporos 8:137. https://doi.org/10.1007/s11657-013-0137-0 CrossRef

Cauley JA (2017) Osteoporosis: fracture epidemiology update 2016. Curr Opin Rheumatol 29:150–1562. https://doi.org/10.1097/BOR.0000000000000365 CrossRefPubMed

Dumic-Cule I, Pecina M, Jelic M, Jankolija M, Popek I, Grgurevic L et al (2015) Biological aspects of segmental bone defects management. Int Orthop 39:005–1011. https://doi.org/10.1007/s00264-015-2728-4 CrossRef

Dimitriou R, Carr IM, West RM, Markham AF, Giannoudis PV (2011) Genetic predisposition to fracture non-union: a case control study of a preliminary single nucleotide polymorphisms analysis of the BMP pathway. BMC Musculoskelet Disord 12(44). https://doi.org/10.1186/1471-2474-12-44

Petrie J, Sassoon A, Haidukewych GJ (2013) When femoral fracture fixation fails: salvage options. Bone Joint J 95-B:7–10. https://doi.org/10.1302/0301-620X.95B11.32896 CrossRefPubMed

Chen Y, Guo Q, Pan X, Qin L, Zhang P (2011) Smoking and impaired bone healing: will activation of cholinergic anti-inflammatory pathway be the bridge? Int Orthop 35:1267–1270. https://doi.org/10.1007/s00264-011-1243-5 CrossRefPubMedPubMedCentral

Flouzat-Lachaniette CH, Heyberger C, Bouthors C, Roubineau F, Chevallier N, Rouard H, Hernigou P (2016) Osteogenic progenitors in bone marrow aspirates have clinical potential for tibial non-unions healing in diabetic patients. Int Orthop 40:1375–1379. https://doi.org/10.1007/s00264-015-3046-6 CrossRefPubMed

Hernigou P, Guissou I, Homma Y, Poignard A, Chevallier N, Rouard H, Flouzat Lachaniette CH (2015) Percutaneous injection of bone marrow mesenchymal stem cells for ankle non-unions decreases complications in patients with diabetes. Int Orthop 39:1639–1643. https://doi.org/10.1007/s00264-015-2738-2 CrossRefPubMed

Vukicevic S, Stavljenic A, Pecina M (1995) Discovery and clinical applications of bone morphogenetic proteins. Eur J Clin Chem Clin Biochem 33:661–671PubMed

10.

Vukicevic S, Sampath TK (2008) Bone morphogenetic proteins: from local to systemic therapeutics. Basel-Boston-Berlin: Birkauser Verlag AG

11.

Grgurevic L, Christensen GL, Schulz TJ, Vukicevic S (2016) Bone morphogenetic proteins in inflammation, glucose homeostasis and adipose tissue energy metabolism. Cytokine Growth Factor Rev 27:105–118. https://doi.org/10.1016/j.cytogfr.2015.12.009 CrossRefPubMed

12.

Urist MR (1965) Bone: formation by autoinduction. Science 150:893–899CrossRef

13.

Grgurevic L, Pecina M, Vukicevic S (2017) Marshall R. Urist and the discovery of bone morphogenetic proteins. Int Orthop 41:1065–1069. https://doi.org/10.1007/s00264-017-3402-9 CrossRefPubMed

14.

Reddi AH, Huggins C (1972) Biochemical sequences in the transformation of normal fibroblasts in adolescent rats. Proc Natl Acta Sci USA 69:1601–1605CrossRef

15.

Vukicevic S, Oppermann H, Verbanac D, Jankolija M, Popek I, Curak J et al (2014) The clinical use of bone morphogenetic proteins (BMPs) revisited: a novel BMP6 biocompatible carrier device OSTEOGROW for bone healing. Int Orthop 38:635–647. https://doi.org/10.1007/s00264-013-2201-1 CrossRefPubMed

16.

Vukicevic S, Sampath TK (ed) (2017) Bone morphogenetic proteins: systems biology regulators, 1st edn Springer International Publishing AG, Switzerland

17.

van Baardewijk LJ, van der Ende J, Lissenberg-Thunnissen S, Romijn LM, Hawinkels LJ, Sier CF, Schipper IB (2013) Circulating bone morphogenetic protein levels and delayed fracture healing. Int Orthop 37:523–527. https://doi.org/10.1007/s00264-012-1750-z CrossRefPubMed

18.

Kamiya N, Ye L, Kobayashi T, Lucas DJ, Mochida Y, Yamauchi M et al (2008) Disruption of BMP signaling in osteoblasts through type IA receptor (BMPRIA) increases bone mass. J Bone Miner Res 23:2007–2017. https://doi.org/10.1359/jbmr.080809 CrossRefPubMedPubMedCentral

19.

Okamoto M, Murai J, Imai Y, Ikegami D, Kamiya N, Kato S et al (2011) Conditional deletion of Bmpr1a in differentiated osteoclasts increases osteoblastic bone formation, increasing volume of remodeling bone in mice. J Bone Miner Res 26:2511–2522. https://doi.org/10.1002/jbmr.477 CrossRefPubMed

20.

Okamoto M, Murai J, Yoshikawa H, Tsumaki N (2006) Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development. J Bone Miner Res 21:1022–1033. https://doi.org/10.1359/jbmr.060411 CrossRefPubMed

21.

Minear S, Leucht P, Miller S, Helms JA (2010) rBMP represses Wnt signaling and influences skeletal progenitor cell fate specification during bone repair. J Bone Miner Res 25:1196–1207. https://doi.org/10.1002/jbmr.29 CrossRefPubMedPubMedCentral

22.

Kamiya N, Kobayashi T, Mochida Y, Yu PB, Yamauchi M, Kronenberg HM et al (2010) Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts. J Bone Miner Res 25:200–210. https://doi.org/10.1359/jbmr.090806 CrossRefPubMed

23.

Giles EM, Godbout C, Chi W, Glick MA, Lin T, Li R, Schemitsch EH, Nauth A (2017) Subtypes of endothelial progenitor cells affect healing of segmental bone defects differently. Int Orthop 41:2337–2343. https://doi.org/10.1007/s00264-017-3613-0 CrossRefPubMed

24.

Bolander J, Chai YC, Geris L, Schrooten J, Lambrechts D, Roberts SJ, Luyten FP (2016) Early BMP, Wnt and Ca(2+)/PKC pathway activation predicts the bone forming capacity of periosteal cells in combination with calcium phosphates. Biomaterials 86:106–118. https://doi.org/10.1016/j.biomaterials.2016.01.059 CrossRefPubMed

25.

Kalfas IH (2001) Principles of bone healing. Neurosurg Focus 10:E1-. https://doi.org/10.3171/foc.2001.10.4.2 CrossRef

26.

Reddi AH, Cunningham NS (1993) Initiation and promotion of bone differentiation by bone morphogenetic proteins. J Bone Miner Res 8(Suppl 2):S499–S502. https://doi.org/10.1002/jbmr.5650081313 CrossRefPubMed

27.

Dimitriou R, Tsiridis E, Giannoudis PV (2005) Current concepts of molecular aspects of bone healing. Injury 36:1392–1404. https://doi.org/10.1016/j.injury.2005.07.019 CrossRefPubMed

28.

Cho TJ, Gerstenfeld LC, Einhorn TA (2002) Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing. J Bone Miner Res 17:513–520. https://doi.org/10.1359/jbmr.2002.17.3.513 CrossRefPubMed

29.

Edgar CM, Chakravarthy V, Barnes G, Kakar S, Gerstenfeld LC, Einhorn TA (2007) Autogenous regulation of a network of bone morphogenetic proteins (BMPs) mediates the osteogenic differentiation in murine marrow stromal cells. Bone 40:1389–1398. https://doi.org/10.1016/j.bone.2007.01.001 CrossRefPubMedPubMedCentral

30.

Cheng H, Jiang W, Phillips FM, Haydon RC, Peng Y, Zhou L et al (2003) Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg Am 85-A:1544–1552. https://doi.org/10.1016/j.urolonc.2003.12.008 CrossRefPubMed

31.

Asahina I, Sampath TK, Nishimura I, Hauschka PV (1993) Human osteogenic protein-1 induces both chondroblastic and osteoblastic differentiation of osteoprogenitor cells derived from newborn rat calvaria. J Cell Biol 123:921–933. https://doi.org/10.1083/jcb.123.4.921 CrossRefPubMed

32.

Onishi T, Ishidou Y, Nagamine T, Yone K, Imamura T, Kato M et al (1998) Distinct and overlapping patterns of localization of bone morphogenetic protein (BMP) family members and a BMP type II receptor during fracture healing in rats. Bone 22:605–612. https://doi.org/10.1016/S8756-3282(98)00056-8 CrossRefPubMed

33.

Dejaeger M, Böhm AM, Dirckx N, Devriese J, Nefyodova E, Cardoen R, St-Arnaud R, Tournoy J, Luyten FP, Maes C (2017) Integrin-linked kinase regulates bone formation by controlling cytoskeletal organization and modulating BMP and Wnt signaling in Osteoprogenitors. J Bone Miner Res 32:2087–2102. https://doi.org/10.1002/jbmr.3190 CrossRefPubMed

34.

Ali IH, Brazil DP (2014) Bone morphogenetic proteins and their antagonists: current and emerging clinical uses. Br J Pharmacol 171:3620–3632. https://doi.org/10.1111/bph.12724 CrossRefPubMedPubMedCentral

35.

Kloen P, Di PM, Borens O, Richmond J, Perino G, Helfet DL, Goumans MJ (2003) BMP signaling components are expressed in human fracture callus. Bone 33:362–371. https://doi.org/10.1016/S8756-3282(03)00191-1 CrossRefPubMed

36.

Kwong FN, Hoyland JA, Evans CH, Freemont AJ (2009) Regional and cellular localisation of BMPs and their inhibitors’ expression in human fractures. Int Orthop 33:281–288. https://doi.org/10.1007/s00264-008-0691-z CrossRefPubMed

37.

Wan DC, Pomerantz JH, Brunet LJ, Kim JB, Chou YF, Wu BM et al (2007) Noggin suppression enhances in vitro osteogenesis and accelerates in vivo bone formation. J Biol Chem 282:26450–26459. https://doi.org/10.1074/jbc.M703282200 CrossRefPubMed

38.

Chhabra A, Zijerdi D, Zhang J, Kline A, Balian G, Hurwitz S (2005) BMP-14 deficiency inhibits long bone fracture healing: a biochemical, histologic, and radiographic assessment. J Orthop Trauma 19:629–634. https://doi.org/10.1097/01.bot.0000177108.38461.9c CrossRefPubMed

39.

Niikura T, Hak DJ, Reddi AH (2006) Global gene profiling reveals a downregulation of BMP gene expression in experimental atrophic nonunions compared to standard healing fractures. J Orthop Res 24:1463–1471. https://doi.org/10.1002/jor.20182 CrossRefPubMed

40.

Kwong FN, Hoyland JA, Freemont AJ, Evans CH (2009) Altered relative expression of BMPs and BMP inhibitors in cartilaginous areas of human fractures progressing towards nonunion. J Orthop Res 27:752–757. https://doi.org/10.1002/jor.20794 CrossRefPubMedPubMedCentral

41.

Kloen P, Lauzier D, Hamdy RC (2012) Co-expression of BMPs and BMP-inhibitors in human fractures and non-unions. Bone 51:59–68. https://doi.org/10.1016/j.bone.2012.03.032 CrossRefPubMed

42.

Fu R, Selph S, McDonagh M, Peterson K, Tiwari A, Chou R et al (2013) Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis. Ann Intern Med 158:890–902. https://doi.org/10.7326/0003-4819-158-12-201306180-00006 CrossRefPubMed

43.

Simmonds MC, Brown JV, Heirs MK, Higgins JP, Mannion RJ, Rodgers MA et al (2013) Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data. Ann Intern Med 158:877–889. https://doi.org/10.7326/0003-4819-158-12-201306180-00005 CrossRefPubMed

44.

Govender S, Csimma C, Genant HK, Valentin-Opran A, Amit Y, Arbel R et al (2002) Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 84-A:2123–2134. https://doi.org/10.2106/00004623-200212000-00001 CrossRefPubMed

45.

Friedlaender GE, Perry CR, Cole JD, Cook SD, Cierny G, Muschler GF et al (2001) Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 83-A(Suppl 1):S151–S158. https://doi.org/10.2106/00004623-200100002-00010 CrossRef

46.

Giannoudis PV, Kanakaris NK (2017) BMPs in orthopaedic medicine: promises and challenges. In: Vukicevic S, Sampath TK (eds) Bone morphogenetic proteins: systems biology regulators, 1st edn. Springer International Publishing AG, Switzerland, pp 187–214CrossRef

47.

Pecina M, Giltaij LR, Vukicevic S (2001) Orthopaedic applications of osteogenic protein-1 (BMP-7). Int Orthop 25:203–208. https://doi.org/10.1007/s002640100262 CrossRefPubMedPubMedCentral

48.

Pecina M, Haspl M, Jelic M, Vukicevic S (2003) Repair of a resistant tibial non-union with a recombinant bone morphogenetic protein-7 (rhBMP-7). Int Orthop 27:320–321. https://doi.org/10.1007/s00264-003-0475-4 CrossRefPubMedPubMedCentral

49.

Bilic R, Simic P, Jelic M, Stern-Padovan R, Dodig D, van Meerdervoort HP et al (2006) Osteogenic protein-1 (BMP-7) accelerates healing of scaphoid non-union with proximal pole sclerosis. Int Orthop 30:128–134. https://doi.org/10.1007/s00264-005-0045-z CrossRefPubMedPubMedCentral

50.

Giannoudis PV, Kanakaris NK, Dimitriou R, Gill I, Kolimarala V, Montgomery RJ (2009) The synergistic effect of autograft and BMP-7 in the treatment of atrophic nonunions. Clin Orthop Relat Res 467:3239–3248. https://doi.org/10.1007/s11999-009-0846-2 CrossRefPubMedPubMedCentral

51.

Crawford CH III, Seligson D (2009) Atrophic nonunion of humeral diaphysis treated with locking plate and recombinant bone morphogenetic protein: nine cases. Am J Orthop (Belle Mead NJ) 38:567–570

52.

von Rüden C, Morgenstern M, Friederichs J, Augat P, Hackl S, Woltmann A, Bühren V, Hierholzer C (2016) Comparative study suggests that human bone morphogenetic proteins have no influence on the outcome of operative treatment of aseptic clavicle non-unions. Int Orthop 40:2339–2345. https://doi.org/10.1007/s00264-016-3262-8 CrossRef

53.

Courvoisier A, Sailhan F, Laffenêtre O, Obert L, French Study Group of BMP in Orthopedic Surgery (2014) Bone morphogenetic protein and orthopaedic surgery: can we legitimate its off-label use? Int Orthop 38:2601–2605. https://doi.org/10.1007/s00264-014-2534-4 CrossRefPubMed

54.

Faundez A, Tournier C, Garcia M, Aunoble S, Le Huec JC (2016) Bone morphogenetic protein use in spine surgery-complications and outcomes: a systematic review. Int Orthop 40:1309–1319. https://doi.org/10.1007/s00264-016-3149-8 CrossRefPubMed

55.

Cahill KS, Chi JH, Day A, Claus EB (2009) Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. JAMA 302:58–66. https://doi.org/10.1001/jama.2009.956 CrossRefPubMed

56.

Laursen M, Høy K, Hansen ES, Gelineck J, Christensen FB, Bünger CE (1999) Recombinant bone morphogenetic protein-7 as an intracorporal bone growth stimulator in unstable thoracolumbar burst fractures in humans: preliminary results. Eur Spine J 8:485–490CrossRef

57.

Wikesjö UME, Susin C (2017) BMPs in dental medicine: promises and challenges. In: Vukicevic S, Sampath TK (eds) Bone morphogenetic proteins: systems biology regulators, 1st edn. Springer International Publishing AG, Switzerland, pp 249–270CrossRef

58.

Fiorellini JP, Howell TH, Cochran D, Malmquist J, Lilly LC, Spagnoli D et al (2005) Randomized study evaluating recombinant human bone morphogenetic protein-2 for extraction socket augmentation. J Periodontol 76:605–613. https://doi.org/10.1902/jop.2005.76.4.605 CrossRefPubMed

59.

Triplett RG, Nevins M, Marx RE, Spagnoli DB, Oates TW, Moy PK et al (2009) Pivotal, randomized, parallel evaluation of recombinant human bone morphogenetic protein-2/absorbable collagen sponge and autogenous bone graft for maxillary sinus floor augmentation. J Oral Maxillofac Surg 67:1947–1960. https://doi.org/10.1016/j.joms.2009.04.085 CrossRefPubMed

60.

Desai SC, Sclaroff A, Nussenbaum B (2013) Use of recombinant human bone morphogenetic protein 2 for mandible reconstruction. JAMA Facial Plast Surg 15:204–209. https://doi.org/10.1001/jamafacial.2013.650 CrossRefPubMed

61.

Clokie CM, Sandor GK (2008) Reconstruction of 10 major mandibular defects using bioimplants containing BMP-7. J Can Dent Assoc 74:67–72PubMed

62.

Ekrol I, Hajducka C, Court-Brown C, McQueen MM (2008) A comparison of rhBMP-7 (OP-1) and autogenous graft for metaphyseal defects after osteotomy of the distal radius. Injury 39(Suppl 2):S73–S82. https://doi.org/10.1016/S0020-1383(08)70018-4 CrossRefPubMed

63.

Dumic-Cule I, Brkljacic J, Rogic D, Bordukalo-Niksic T, Tikvica Luetic A, Draca N et al (2014) Systemically available bone morphogenetic protein two and seven affect bone metabolism. Int Orthop 38:1979–1985. https://doi.org/10.1007/s00264-014-2425-8 CrossRefPubMed

64.

Pradhan BB, Bae HW, Dawson EG, Patel VV, Delamarter RB (2006) Graft resorption with the use of bone morphogenetic protein: lessons from anterior lumbar interbody fusion using femoral ring allografts and recombinant human bone morphogenetic protein-2. Spine (Phila Pa 1976) 31:E277–E284. https://doi.org/10.1097/01.brs.0000216442.12092.01 CrossRef

65.

Krishnakumar GS, Roffi A, Reale D, Kon E, Filardo G (2017) Clinical application of bone morphogenetic proteins for bone healing: a systematic review. Int Orthop 41:1073–1083. https://doi.org/10.1007/s00264-017-3471-9 CrossRefPubMed

66.

Vukicevic S, Grgurevic L, Pecina M (2017) Clinical need for bone morphogenetic proteins. Int Orthop 41:2415–2416. https://doi.org/10.1007/s00264-017-3550-y CrossRefPubMed

67.

Song K, Krause C, Shi S, Patterson M, Suto R, Grgurevic L et al (2010) Identification of a key residue mediating bone morphogenetic protein (BMP)-6 resistance to noggin inhibition allows for engineered BMPs with superior agonist activity. J Biol Chem 285:12169–12180. https://doi.org/10.1074/jbc.M109.087197 CrossRefPubMedPubMedCentral

Title: Bone morphogenetic proteins in fracture repair
Authors: Ivo Dumic-Cule
Mihaela Peric
Lucija Kucko
Lovorka Grgurevic
Marko Pecina
Slobodan Vukicevic
Publication date: 01-11-2018
Publisher: Springer Berlin Heidelberg
Published in: International Orthopaedics / Issue 11/2018
Print ISSN: 0341-2695
Electronic ISSN: 1432-5195
DOI: https://doi.org/10.1007/s00264-018-4153-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Bone morphogenetic proteins in fracture repair

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2018

Vertical shear pelvic injury: evaluation, management, and fixation strategies

In vivo kinematics of gait in posterior-stabilized and bicruciate-stabilized total knee arthroplasties using image-matching techniques

Altering polymerization temperature of antibiotic-laden cement can increase porosity and subsequent antibiotic elution

“Partial extensor mechanism allograft reconstruction for chronic patellar tendon disruption shows superior outcomes in native knees when compared to same technique following total arthroplasty”: several questions

Subchondral stem cell therapy versus contralateral total knee arthroplasty for osteoarthritis following secondary osteonecrosis of the knee

Clinical outcomes following arthroscopic treatment of femoro-acetabular impingement using a minimal traction approach and an initial capsulotomy. Minimum two year follow-up